Prohepar® –
Complex protection of liver

 Verabreichungsform / Tabletten
 Wirkstoff / Liver Extract N 70 mg
 Besonderheit / Hergestellt in Deutschland

Produktangaben

Composition

  • Liver Extract N(liver hydrolysate from bovine cattle with min 1,5 cyanocobalamin) 70 mg
  • L-cysteine hydrochloride 20 mg
  • Choline hydrogentartrate 100 mg
  • Myo-inositol 25 mg

ATC-classification A05BA

Pharmacological properties

Prohepar® protects and regenerates the structure of hepatocytes, inhibits the growth of connective tissues in liver, stimulates regeneration of those parts of the liver parenchyma which have been destroyed. Prohepar® supports improvement of local blood circulation in liver tissues, enhances renal elimination and improves criteria of liver function.

Indications

Prohepar® is indicated as part of complex therapy to treat chronic hepatitis, liver dystrophies, nonalcoholic fatty liver disease, toxic liver disease of various etiologies i. e. alcoholic, virus hepatitis and drug-induced liver injury, liver cirrhosis and hepatopathies of different origins.

Publikationen klinischer Studien

Russland

Publikation auf rusmedreview.com lesen
Publikation auf clinvest.ru lesen

Ukraine

Publikation auf gastro.zaslavsky.com.ua lesen

Prohepar® advantages

  • High-quality German product Produced in Germany, Certification GMP (EU)
  • Multicomponent composition (4 API’s) guarantees high therapeutic efficiency
  • High bioavailability
  • Proved clinical efficacy in alcoholic liver disease, NAFLD (steatohepatitis), drug-induced liver injury and chronic hepatitis.
  • Stable substance

Prohepar® complex hepatoprotector

  • 4 Active components Liver extract N, L-cysteine, Choline and Myo-inositol
  • Product form coated tablets
  • Packaging 50 or 100 tablets in a plastic vial
  • Pharmacy purchasing terms OTC
  • German Highest Quality
  • Efficiency of the drug is clinically proven
  • High bioavailability

Prohepar® clinic base

  • More than 8 conducted clinic studies in Russia for the last 4 years
  • More than 500 patients
  • 2 conducted clinic studies in Ukraine since registration in 2014
  • 3 clinic studies in process in Russia, Ukraine and Azerbaijan